Rivastigmine for the management of anticholinergic delirium

References

• Dawson AH, Buckley NA. Pharmacological management of anticholinergic delirium – theory, evidence and practice. Br J Clin Pharmacol. 2016;81(3):516–524. doi: 10.1111/bcp.12839.
   PubMed Web of Science ®Google Scholar
• Burns MJ, Linden CH, Graudins A, et al. A comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning. Ann Emerg Med. 2000;35(4):374–381. doi: 10.1016/S0196-0644(00)70057-6.
   PubMed Web of Science ®Google Scholar
• Triggle DJ, Mitchell JM, Filler R. The pharmacology of physostigmine. CNS Drug Rev. 1998;4(2):87–136. doi: 10.1111/j.1527-3458.1998.tb00059.x.
   Google Scholar
• Wang GS, Baker K, Ng P, et al. A randomized trial comparing physostigmine vs lorazepam for treatment of antimuscarinic (anticholinergic) toxidrome. Clin Toxicol (Phila). 2021;59(8):698–704. doi: 10.1080/15563650.2020.1854281.
   PubMed Web of Science ®Google Scholar
• Arens AM, Kearney T. Adverse effects of physostigmine. J Med Toxicol. 2019;15(3):184–191. doi: 10.1007/s13181-019-00697-z.
   PubMed Web of Science ®Google Scholar
• Greene SC. Rivastigmine use in the treatment of antimuscarinic delirium. J Med Toxicol. 2023;19(3):284–287. doi: 10.1007/s13181-023-00947-1.
   PubMed Web of Science ®Google Scholar
• Correia MS, Hendrickson RG. Improvement in delirium and visuospatial function after rivastigmine in antimuscarinic toxicity: a case report. Toxicol Commun. 2023;7(1):2253688.
   Google Scholar
• Watkins JW, Schwarz ES, Arroyo-Plasencia AM, et al. The use of physostigmine by toxicologists in anticholinergic toxicity. J Med Toxicol. 2015;11(2):179–184. doi: 10.1007/s13181-014-0452-x.
   PubMed Web of Science ®Google Scholar
• Pentel P, Peterson CD. Asystole complicating physostigmine treatment of tricyclic antidepressant overdose. Ann Emerg Med. 1980; Nov9(11):588–590. doi: 10.1016/s0196-0644(80)80232-0.
   PubMed Web of Science ®Google Scholar
• Fratta KA, Ginder M, Haggerty DA. Oral and transdermal rivastigmine for the treatment of anticholinergic delirium: a case report. J Emerg Med. 2023;65(4):e366–e368. doi: 10.1016/j.jemermed.2023.06.008.
   PubMed Web of Science ®Google Scholar
• Van Kernebeek MW, Ghesquiere M, Vanderbruggen N, et al. Rivastigmine for the treatment of anticholinergic delirium following severe procyclidine intoxication. Clin Toxicol (Phila). 2021;59(5):447–448. doi: 10.1080/15563650.2020.1818768.
   PubMed Web of Science ®Google Scholar
• Hughes AR, Moore KK, Mah ND, et al. Letter in response to rivastigmine for the treatment of anticholinergic delirium following severe procyclidine intoxication. Clin Toxicol (Phila). 2021;59(9):855–856. doi: 10.1080/15563650.2020.1869757.
   PubMed Web of Science ®Google Scholar
• Marucci G, Buccioni M, Ben DD, et al. Efficacy of acetylcholinesterase inhibitors in alzheimer’s disease. Neuropharmacology. 2021;190:108352. doi: 10.1016/j.neuropharm.2020.108352.
   PubMed Web of Science ®Google Scholar
• Kandiah N, Pai MC, Senanarong V, et al. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and parkinson’s disease dementia. Clin Interv Aging. 2017;12:697–707. doi: 10.2147/CIA.S129145.
   PubMed Web of Science ®Google Scholar
• Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of alzheimer’s disease. Clin Ther. 1998;20(4):634–647. doi: 10.1016/s0149-2918(98)80127-6.
   PubMed Web of Science ®Google Scholar
• Kennedy JS, Polinsky RJ, Johnson B, et al. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans. J Clin Psychopharmacol. 1999;19(6):513–521. doi: 10.1097/00004714-199912000-00005.
   PubMed Web of Science ®Google Scholar
• Nieto RA, Deardorff WJ, Grossberg GT. Efficacy of rivastigmine tartrate, transdermal system, in alzheimer’s disease. Expert Opin Pharmacother. 2016;17(6):861–870. doi: 10.1517/14656566.2016.1159296.
   PubMed Web of Science ®Google Scholar
• Exelon Patch. (rivastigmine) [prescribing information]. Novartis Pharmaceutical Corporation, East Hanover. Revised June 2020. https://www.pharma.us.novartis.com/product/pi/pdf/exelonpatch.pdf. Accessed 24th Oct 2023.
   Google Scholar
• Kurz A, Farlow M, Lefèvre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of alzheimer’s disease: a review. Int J Clin Pract. 2009;63(5):799–805. doi: 10.1111/j.1742-1241.2009.02052.x.
   PubMed Web of Science ®Google Scholar
• Mercier F, Lefèvre G, Huang HL, et al. Rivastigmine exposure provided by a transdermal patch versus capsules. Curr Med Res Opin. 2007;23(12):3199–3204. doi: 10.1185/030079908X253438.
   PubMed Web of Science ®Google Scholar
• Cutler NR, Polinsky RJ, Sramek JJ, et al. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in alzheimer’s disease. Acta Neurol Scand. 1998;97(4):244–250. doi: 10.1111/j.1600-0404.1998.tb00645.x.
   PubMed Web of Science ®Google Scholar
• Lefèvre G, Sedek G, Jhee SS, et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in alzheimer’s disease patients. Clin Pharmacol Ther. 2008;83(1):106–114. doi: 10.1038/sj.clpt.6100242.
   PubMed Web of Science ®Google Scholar